COVID-19 Implications for I-O Patient Management

Latest Discussion Posts

  • Profile Picture

    RE: Shared Resources

    The National Cancer Institute (NCI) has released two Request for Applications (RFAs) for components of the new Serological Sciences Network (SeroNet). The two RFAs are for  U01 Research Projects in SARS-CoV-2 Serological Sciences  and  U54 SARS-CoV-2 ...

  • Profile Picture

    RE: Shared Resources

    BTK Inhibition for COVID-19 In a prospective, off-label study, the selective Bruton tyrosine kinase inhibitor acalabrutinib was administered off-label to 19 patients hospitalized with severe COVID-19 (11 on supplemental oxygen; 8 on mechanical ventilation). ...

  • Profile Picture

    RE: Shared Resources

    Virtual Symposium Announcement: Cytokines in COVID-19 The NIH/FDA Immunology Interest Group and the NIH/FDA Cytokine Interest Group is holding a seminar on June 18, 2020, 9:00am - 1:45pm ET. Topics will include the dynamic cytokine response over the ...

  • Results from Italian TOCIVID-19 clinical trial of tocilizumab Finally we have data from TOCIVID-19 clinical trial about tocilizumab use. Analysis on 301 patients enrolled for the phase 2 study (in only 20 hours between March 19 and 20) and 920 patients ...

  • Profile Picture

    RE: Shared Resources

    Mayo Clinic randomized phase 2 trial investigating TRMPRSS2 serine protease inhibitor for COVID-19 SARS-CoV-2 has been shown to use the ACE2 and TMPRSS2 receptors for cell entry. The primary study objective is to determine if reduction in TMPRSS2 activity ...

Latest Shared Files